

AISAP presentation

Amit Aharoni

AISAP - Biomed abstract submission

Company name: AISAP LTD; Website: <https://www.aisap.ai/>

CEO name: Eran Taus; Email - erant@aisap.ai

Applicant details:

Name - Amit Aharoni; Position - VP of Business and Strategy

Email - amita@aisap.ai; Cell phone - 0546451068

Category: Health IT/Digital health

SESSION - AI as an Equalizer: From Center to Periphery in Healthcare

1. **Executive Summary / Investment Rational:** AISAP transforms bedside diagnostics with FDA-cleared AI for Point-of-Care Ultrasound (POCUS). Having raised a \$20M extended seed round, with headquarters in Ramat gan and NYC, we are scaling across global markets. Our unique blend of elite technologists and senior clinicians leverages proprietary medical databases to accelerate R&D, securing strategic partnerships with major U.S. health systems and medical device leaders.
2. **Core Technology:** Our PocusOS™ is the first AI operating system for point-of-care ultrasound. It features POCAD™, the only multi-CADx AI solution with FDA clearance, providing >93% sensitivity and specificity for 12 cardiac AI models. Our unique value is enabling non-experts to deliver expert-level cardiac assessments at the bedside, bridging the gap between specialized urban centers and underserved peripheral or rural communities.
3. **Product Profile/Pipeline:** Current products, POCAD™ and PocusOS™, are operational in world-leading medical centers. Our pipeline includes a total-body AI diagnostic approach - expanding to vascular, abdominal, and lung protocols by 2026-27. Key milestones include deep integration with Vendor-agnostic Cloud/EMR/PACS/Ultrasound vendors and systems. We seek partnerships with health networks to standardize AI-powered triage across rural/community-based hospitals and private cardiology groups/practices.
4. **Business Strategy:** We are actively commercializing in the U.S., Israel, and Australia via a direct SaaS subscription model. To achieve rapid scale, we are securing strategic partnerships with ultrasound OEMs, PACS, and Enterprise Imaging companies. This hybrid approach enables us to reach the U.S. mainstream market efficiently, delivering near-term recurring revenue and long-term dominance as a global diagnostic company.

5. **What's Next?** We are expanding our proprietary database of millions of frames and executing clinical validations with Mayo Clinic and Stanford. Strategically, we are securing multi-year enterprise contracts, targeting high-margin growth as the first-to-market universal AI operating system. We expect to accelerate global operations and R&D through a significant Series A funding round in 2026.